Work

Minimal residual disease detected prior to hematopoietic cell transplantation

Year: 2011

Type: article

Abstract: Previous studies to evaluate minimal disease in acute lymphoblastic leukemia (ALL) after treatment have relied on the diagnostic specimen to develop patient-specific analytical probes. The diagnostic specimen is often not available in a tertiary setting; therefore, we evaluated the use of flow cytometry (FCM) using a "difference from normal" approach to detect residual disease prior to myeloablative allogeneic hematopoietic cell transplantation (HCT). Among 116 pediatric patients with ALL who were in morphological remission at time of transplant, we found that those patients who had detectable residual disease by FCM prior to HCT experienced significantly inferior outcome.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.23079

Authors: Jennifer H. Foster, Douglas S. Hawkins, Michael R. Loken, Denise A. Wells, Blythe Thomson

Institutions: Baylor College of Medicine, Seattle Children's Hospital

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Center for Research Resources